Seven Hills Partners

7 Hills Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class integrin activators to enhance the effectiveness of immunotherapies and vaccines. The company's lead candidate, alintegimod (7HP349), is a systemic small molecule designed to activate VLA-4 and LFA-1 integrins, thereby improving immune cell adhesion and trafficking to tumors. This approach aims to overcome resistance to checkpoint inhibitors and augment the immune response to infectious disease vaccines. Additionally, the company is advancing programs in hematopoietic stem cell transplantation (HSCT) to improve outcomes for patients with leukemias and genetic disorders.